Zacks Research Downgrades Hyperion DeFi (NASDAQ:HYPD) to Strong Sell

Hyperion DeFi (NASDAQ:HYPD) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other brokerages have also weighed in on HYPD. Chardan Capital reiterated a “buy” rating and set a $7.30 price objective on shares of Hyperion DeFi in a report on Tuesday. Cantor Fitzgerald raised their target price on Hyperion DeFi from $6.60 to $7.10 and gave the company an “overweight” rating in a research note on Thursday. Finally, Weiss Ratings raised Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.20.

Hyperion DeFi Stock Performance

NASDAQ:HYPD opened at $2.83 on Wednesday. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12. Hyperion DeFi has a twelve month low of $2.34 and a twelve month high of $15.00. The company has a fifty day moving average of $2.91 and a 200-day moving average of $3.36. The firm has a market capitalization of $42.90 million, a P/E ratio of -0.43 and a beta of 2.53.

Hyperion DeFi (NASDAQ:HYPD) last issued its earnings results on Thursday, August 13th. The company reported $0.92 earnings per share (EPS) for the quarter. The business had revenue of $0.36 million for the quarter. Hyperion DeFi had a net margin of 416.56% and a negative return on equity of 13.93%. As a group, sell-side analysts anticipate that Hyperion DeFi will post 1.69 EPS for the current year.

Insider Transactions at Hyperion DeFi

In other Hyperion DeFi news, insider Hyunsu Jung purchased 7,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was acquired at an average price of $3.70 per share, for a total transaction of $25,900.00. Following the purchase, the insider owned 1,384,676 shares of the company’s stock, valued at $5,123,301.20. This trade represents a 0.51% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HYPD. Redwood Wealth Management Group LLC grew its holdings in shares of Hyperion DeFi by 2.1% during the first quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock valued at $632,000 after buying an additional 3,690 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Hyperion DeFi in the 4th quarter valued at about $73,000. State Street Corp bought a new position in Hyperion DeFi in the 4th quarter valued at about $92,000. Jane Street Group LLC acquired a new position in Hyperion DeFi during the 4th quarter valued at about $493,000. Finally, Renaissance Technologies LLC bought a new stake in Hyperion DeFi during the 4th quarter worth approximately $663,000. 25.84% of the stock is owned by institutional investors.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.